Clearside Announces Pricing of Public Offering of Common Stock

Pharmaceutical Investing

Clearside Biomedical (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the pricing of its underwritten public offering of 6,538,462 shares of its common stock at a price to the public of $13.00 per share. As quoted in the press release: J.P. Morgan Securities LLC and Cowen and …

As quoted in the press release:

J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Stifel, Nicolaus & Company, Incorporated is acting as a passive book-running manager and Needham & Company, LLC and Wedbush Securities Inc. are acting as co-managers for the offering. Clearside has granted to the underwriters a 30-day option to purchase up to 980,769 additional shares of common stock at the public offering price, less the underwriting discount.

Click here to read the full press release.

biomedical clearside biomedical j.p. morgan public offering stifel stifel nicolaus underwritten public offering Pharmaceutical Investing